(132 days)
ScrewIndirect Narrow Dental Implants are implants for single-stage surgical procedures intended for use in partially or fully edentulous mandibles and maxillae, in support of complete or partial denture prostheses or as a terminal or intermediary attachment for fixed or removable bridgework via interface with copings. These implants are intended for immediate loading for support of splinted multiple tooth restorations, provided initial implant stability and appropriate occlusal load requirements are met.
The ScrewIndirect Narrow Dental Implants consist of tapered screw-type endosseous implants with the same standard "V" thread configuration, the same 2mm of mini-threads near the top of each implant, are manufactured using the same medical grade titanium alloy material and are coated with the same soluble blast media (SBM). The 3.0mmD implants are in addition to previously approved implants in this system, and are the sole subject of this submission.
The provided text describes a 510(k) summary for the "ScrewIndirect Narrow Dental Implants" (K080633). This is a premarket notification for a medical device that demonstrates substantial equivalence to a legally marketed predicate device.
Key takeaway: The submission focuses on adding a new diameter (3.0mm) to an already approved product family. Therefore, no new clinical studies or detailed performance data are presented, as the device is considered substantially equivalent to the predicate device (Implant Direct's Spectra-System K061319).
As such, the information typically requested in your query (acceptance criteria, device performance tables, sample sizes, expert ground truth, adjudication methods, MRMC studies, standalone performance, and training set details) is not applicable or available in this type of 510(k) submission. The FDA clearance is based on demonstrating that the new 3.0mm diameter implant has the same physical dimensions, material composition, and manufacturing process as the previously approved implants in the family (K061319).
Therefore, I cannot populate the table or answer the specific numbered questions with data from the provided text.
This 510(k) relies on the existing clearance of the predicate device (K061319) and demonstrates substantial equivalence by showing that the modification (new diameter) does not raise new questions of safety or effectiveness. The FDA's review process for such submissions focuses on comparative analysis with the predicate, rather than requiring new, extensive performance studies like those seen for novel devices or PMAs.
§ 872.3640 Endosseous dental implant.
(a)
Identification. An endosseous dental implant is a prescription device made of a material such as titanium or titanium alloy that is intended to be surgically placed in the bone of the upper or lower jaw arches to provide support for prosthetic devices, such as artificial teeth, in order to restore a patient's chewing function.(b)
Classification. (1) Class II (special controls). The device is classified as class II if it is a root-form endosseous dental implant. The root-form endosseous dental implant is characterized by four geometrically distinct types: Basket, screw, solid cylinder, and hollow cylinder. The guidance document entitled “Class II Special Controls Guidance Document: Root-Form Endosseous Dental Implants and Endosseous Dental Implant Abutments” will serve as the special control. (See § 872.1(e) for the availability of this guidance document.)(2)
Classification. Class II (special controls). The device is classified as class II if it is a blade-form endosseous dental implant. The special controls for this device are:(i) The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use;
(ii) Mechanical performance (fatigue) testing under simulated physiological conditions to demonstrate maximum load (endurance limit) when the device is subjected to compressive and shear loads;
(iii) Corrosion testing under simulated physiological conditions to demonstrate corrosion potential of each metal or alloy, couple potential for an assembled dissimilar metal implant system, and corrosion rate for an assembled dissimilar metal implant system;
(iv) The device must be demonstrated to be biocompatible;
(v) Sterility testing must demonstrate the sterility of the device;
(vi) Performance testing to evaluate the compatibility of the device in a magnetic resonance (MR) environment;
(vii) Labeling must include a clear description of the technological features, how the device should be used in patients, detailed surgical protocol and restoration procedures, relevant precautions and warnings based on the clinical use of the device, and qualifications and training requirements for device users including technicians and clinicians;
(viii) Patient labeling must contain a description of how the device works, how the device is placed, how the patient needs to care for the implant, possible adverse events and how to report any complications; and
(ix) Documented clinical experience must demonstrate safe and effective use and capture any adverse events observed during clinical use.